Result of AGM
Eden Research plc announced that all resolutions were passed at its Annual General Meeting, with strong support for the annual report, auditor re-appointment, and director re-elections, though resolutions concerning share allotment and pre-emption rights saw around 5-6% opposition. The company also resolved to change its name to Eden BioSolutions plc to better reflect its focus on sustainable farming solutions, with the change expected to be effective in November 2026.
Select text to share a quote on X · sign in to keep highlights & notes in your EDEN notes
Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technology for global agriculture, announces that at the Annual General Meeting (“AGM”) held today, all resolutions were duly passed.
The total number of votes received by proxy on each resolution, as more fully disclosed in the Notice of AGM available on the Company's website, was as follows:
| Resolution | For | % | Against | % | Withheld | |
|---|---|---|---|---|---|---|
| 1 | To lay the 2026 annual report | 478,509,927 | 99.97 | 129,342 | 0.03 | 3,734,760 |
| 2 | Re-appoint auditors | 477,630,386 | 99.80 | 934,939 | 0.20 | 3,808,704 |
| 3 | Re-elect Sean Smith | 477,744,097 | 99.17 | 4,021,545 | 0.83 | 608,387 |
| 4 | Re-elect Robin Cridland | 453,000,434 | 99.12 | 4,021,751 | 0.88 | 25,351,844 |
| 5 | Re-elect Lykele van der Broek | 452,936,434 | 99.10 | 4,121,751 | 0.90 | 25,315,844 |
| 6 | Re-elect Alex Abrey | 477,844,097 | 99.17 | 4,021,545 | 0.83 | 508,387 |
| 7 | Grant authority to the Directors to allot Ordinary Shares | 455,790,434 | 94.50 | 26,502,049 | 5.50 | 81,546 |
| 8 | Disapply statutory pre-emption rights on allotment of shares* | 454,470,486 | 94.23 | 27,830,680 | 5.77 | 72,863 |
| 9 | To approve the Remuneration Report | 453,287,293 | 94.01 | 28,858,349 | 5.99 | 228,387 |
| 10 | To approve the Remuneration Policy | 452,945,940 | 93.94 | 29,199,702 | 6.06 | 228,387 |
Notes:
* denotes Special Resolution.
A vote Withheld is not a vote in law and is not counted in the calculation of the votes cast For or Against the resolution, nor in the calculation of the percentage of issued share capital voted for any resolution.
Votes For and Against are expressed as a percentage of votes validly cast for that resolution by proxy, excluding any Withheld votes.
Change of Name
The Board has resolved, in accordance with the Company’s Articles, to change the Company’s name to Eden BioSolutions plc to better reflect its endeavours as a provider of solutions for the future of farming. The Company’s core focus is on developing and selling sustainable crop protection solutions for professional agriculture including fungicides, nematicides, seed treatments and insecticides.
The name change is expected to be confirmed shortly and in November 2026 the Company will provide an updated URL for its corporate website and AIM Rule 26 filings. A further announcement will be made once the name change is effective and the Registrar of Companies has issued a change of name certificate.
Investor presentation
A presentation delivered to shareholders at this morning’s AGM is available to view here:
| Eden Research plc | www.edenresearch.com |
| Sean Smith, Chief Executive Officer | Via Walbrook PR |
| Alex Abrey, Chief Financial Officer | |
| Cavendish Capital Markets Limited (Nominated advisor and joint broker) | Tel: 020 7220 0500 |
| Giles Balleny / Elysia Bough (Corporate Finance) | |
| Harriet Ward (Corporate Broking) / Dale Bellis (Sales) | |
| Oberon Capital (Joint Broker) | Tel: 020 3179 5300 |
| Nick Lovering / Mike Seabrook / Adam Pollock | |
| Walbrook PR (Media Relations & Investor Relations) | Tel: 020 7933 8780 or eden@walbrookpr.com |
Paul McManus / Nick Rome / Anna Dunphy
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.